EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2+, basal-like, and HER2 intrinsic subtypes of breast cancer
Savas D. Soysal(University of Basel), W.E. Gillanders(Washington University in St. Louis), Daniel Oertli(University Hospital of Basel), E.C. Obermann(University Hospital of Basel), Gilbert Spizzo(Tyrolean Cancer Research Institute), Timothy P. Fleming, C. T. Viehl(University Hospital of Basel), Thanh U. Barbie(Brigham and Women's Hospital), Simone Muenst(University Hospital of Basel), Feng Gao(Washington University in St. Louis)
Cited by 140
Related Papers
Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses
|Nature Medicine|2018|317
The immune system and cancer evasion strategies: therapeutic concepts
|Journal of Internal Medicine|2016|305
Inhibition of <i>KRAS</i> -Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit
|Cancer Discovery|2014|195
Neratinib Efficacy and Circulating Tumor DNA Detection of <i>HER2</i> Mutations in <i>HER2</i> Nonamplified Metastatic Breast Cancer
|Clinical Cancer Research|2017|191